Trial Profile
Anti-TSLP (AMG 157) Plus Antigen-Specific Immunotherapy for Induction of Tolerance in Individuals With Cat Allergy (ITN057AD)
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 17 Oct 2022
Price :
$35
*
At a glance
- Drugs Tezepelumab (Primary) ; Immunotherapies
- Indications Hypersensitivity
- Focus Therapeutic Use
- 09 Oct 2022 Primary endpoint (Total Nasal Symptom Score (TNSS) Area Under the Curve (AUC)) has not been met, according to Results published in the Journal of Allergy and Clinical Immunology.
- 09 Oct 2022 Results published in the Journal of Allergy and Clinical Immunology
- 09 Apr 2019 Status changed from active, no longer recruiting to completed.